Stock RGLS REGULUS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
1.785 USD -11.85% Intraday chart for Regulus Therapeutics Inc. -28.88% +39.45%
06-25 Canaccord Genuity Raises Price Target on Regulus Therapeutics to $28 From $11, Maintains Buy Rating MT
06-25 HC Wainwright Raises Regulus Therapeutics Price Target to $10 From $9, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Regulus Therapeutics Says Potential Kidney Disease Drug Well-Tolerated in Phase 1b Study
MT
Top Premarket Gainers
MT
Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
CI
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration
CI
Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Regulus Therapeutics Advances to Cohort 4 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
CI
Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
CI
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease
CI
Regulus Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
CI
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease
CI
Regulus Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
CI
Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
CI
Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease
CI
Sanofi Terminates Second Amended and Restated Collaboration and License Agreement with Regulus Therapeutics Inc
CI
Regulus Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGLS Stock
  4. News Regulus Therapeutics Inc.
  5. Highlights